liposomal irinotecan

This page shows the latest liposomal irinotecan news and features for those working in and with pharma, biotech and healthcare.

Shire offloads oncology unit to Servier for $2.4bn

The Dublin-based company said the deal covers its already-marketed drug Oncaspar (pergaspargase) for acute lymphoblastic leukaemia (ALL), as well as ex-US rights to pancreatic cancer therapy Onivyde (irinotecan ... pegylated liposomal formulation) and

Latest news

NICE knocks-back Shire's pancreatic cancer drug Onivyde

NICE has ruled that Shire’s pancreatic cancer drug Onivyde (pegylated liposomal irinotecan) is not a cost-effective use of NHS resources. ... NICE said in a statement: “Although this analysis was subject to considerable uncertainty, the committee was
Ipsen buys cancer business from stripped down Merrimack

The deal includes Onivyde (liposomal irinotecan) and Merrimack's generic version of Doxil (liposomal doxorubicin), as well as the manufacturing and commercial operations supporting the two products.
Shire wins EU licence for pancreatic cancer drug Onivyde

EU. Authorised as a second-line combination therapy, Onivyde (pegylated liposomal irinotecan hydrochloride trihydrate) will be administered with 5-fluorouracil (5-FU) and leucovorin (LV) in adult patients who have progressed
HIV prevention pill heads July CHMP recommendations

The CHMP also gave a positive opinion for Shire's Onivyde (pegylated irinotecan liposomal formulation) for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin,

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Accelerating innovation

At the start of this year it acquired Merrimack’s oncology business, including Onivyde (liposomal irinotecan), for $575m.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Account Manager or AD - Medical Communications: Salary TBC

Medical Writer - (London, Brighton or Copenhagen): Competitive

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior Programme Executive: Salary TBC

Editorial Director – Medical Education – Oxford: Negotiable

Senior Account Manager – Med Comms – Kent: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Account Manager – Med Comms – London: Salary TBC

Project Manager, Medical Communications, Oxford: Excellent Salary

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Account Manager / Account Director: Great salary and bebefits

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Scientific Director: Great salary and bebefits

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Project Manager, Medical Communications, London: Excellent Salary

Medical Writer, e-learning/ training, London: Excellent Salary

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Subscribe to our email news alerts

No results were found

PMHub

Add my company

Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...